Physician
General Surgery
Dr. Jeremy Gates, MD
|
|
Give Review
Jeremy Gates, MD is an expert in the field of General Surgery. He received awards:"Fellow (FACS)". Jeremy Gates is a published doctor. He has 18 papers published. The most current publication "Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix."
Publications
- Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Grou...
- Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and...
- Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
- Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clin...
- Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?
- The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
- Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
- Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01...
- Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
- Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.
- Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma.
- Monitoring circulating tumor cells in cancer vaccine trials.
- AE37: a novel T-cell-eliciting vaccine for breast cancer.
- Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
- Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
- Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from U...
- Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism.
Schools
Creighton Univ Sch Of Med
Brooke Army McFt Sam Houston
Doctors Specialties
- General Surgery
Accepted Insurances
- TriCare for Life
Awards
- Fellow (FACS)
Helpful Reviews
Similar Doctors
|
|
Dr. Rebecca M. McGuigan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Richards, MD |
|
|
Dr. Kenneth L. Goldman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linda C. Benavides, MD |
|
|
Dr. Jose L. Dominguez, MD |
|
|
Dr. Cynthia L. Weber, MD |